Supernus Pharmaceuticals (NASDAQ:SUPN) Shares Gap Up - Here's Why

Key Points

• Supernus Pharmaceuticals shares jumped: The stock opened at $44.24, up from its prior close of $41.08, and last traded at $43.41.
• Analyst sentiment remains cautious: Ratings include one Buy, one Hold, and two Sell recommendations, producing an overall “Reduce” consensus despite a $62.33 average price target.
• Quarterly results were mixed: Supernus missed earnings expectations with a loss of $1.01 per share, but revenue rose 32.4% year over year to $219.06 million, exceeding forecasts.

Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Get Free Report) gapped up prior to trading on Thursday. The stock had previously closed at $41.08, but opened at $44.24. Supernus Pharmaceuticals shares last traded at $43.41, with a volume of 75,670 shares trading hands.

Analysts Set New Price Targets

SUPN has been the subject of several recent research reports. Weiss Ratings reissued a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research report on Monday, September 21st. Wall Street Zen downgraded Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Cantor Fitzgerald increased their price objective on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the company an "overweight" rating in a research note on Thursday, July 9th. Finally, Zacks Research cut Supernus Pharmaceuticals from a "hold" rating to a "strong sell" rating in a research report on Monday, October 5th. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Supernus Pharmaceuticals presently has an average rating of "Reduce" and a consensus target price of $62.33.

Supernus Pharmaceuticals Stock Performance

The stock's fifty day simple moving average is $42.75 and its two-hundred day simple moving average is $47.41. The company has a market cap of $2.47 billion, a price-to-earnings ratio of -22.08, a price-to-earnings-growth ratio of 1.20 and a beta of 0.55.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last issued its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) earnings per share for the quarter, missing the consensus estimate of $0.42 by ($1.43). Supernus Pharmaceuticals had a positive return on equity of 11.13% and a negative net margin of 13.23%. The firm had revenue of $219.06 million during the quarter, compared to analysts' expectations of $205.31 million. During the same period last year, the business posted $0.40 earnings per share. The company's quarterly revenue was up 32.4% compared to the same quarter last year. Analysts predict that Supernus Pharmaceuticals, Inc. will post 1.79 EPS for the current fiscal year.

Institutional Investors Weigh In On Supernus Pharmaceuticals

A number of large investors have recently modified their holdings of the stock. Mystic Asset Management Inc. bought a new position in shares of Supernus Pharmaceuticals during the 2nd quarter valued at about $1,181,000. Bank of America Corp DE bought a new stake in Supernus Pharmaceuticals during the second quarter worth approximately $28,887,000. BlackRock Inc. acquired a new position in Supernus Pharmaceuticals in the second quarter worth approximately $434,871,000. The Manufacturers Life Insurance Company acquired a new position in Supernus Pharmaceuticals in the second quarter worth approximately $1,298,000. Finally, Great Lakes Advisors LLC bought a new position in shares of Supernus Pharmaceuticals in the second quarter valued at $1,386,000.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for disorders of the central nervous system. The company's activities center on epilepsy, attention-deficit/hyperactivity disorder (ADHD), and other neurological conditions, with an emphasis on products designed to provide differentiated dosing or delivery characteristics.

Supernus' marketed products include Trokendi XR (topiramate extended-release) for the prevention of migraine headaches and the treatment of certain seizure disorders, Oxtellar XR (oxcarbazepine extended-release) for partial-onset seizures, and Qelbree (viloxazine extended-release) for ADHD in patients six years of age and older.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.